Home › Funds › Atlas Venture Life Science Advisors, LLC › KYMR
Atlas Venture Life Science Advisors, LLC position in KYMR
KYMERA THERAPEUTICS INC · Health Care
Atlas Venture Life Science Advisors, LLC reported holding 2,847,541 shares of KYMR (KYMERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$318.3M, representing 50.43% of its reported portfolio and ranking #1 among its reported holdings. Atlas Venture Life Science Advisors, LLC has disclosed KYMR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Atlas Venture Life Science Advisors, LLC's KYMR position evolved
Atlas Venture Life Science Advisors, LLC first disclosed a stake in KYMR in Q3 2023 at 5,858,262 shares (US$81.4M). The position peaked in Q1 2026 at 4,578,008 shares, worth US$381.3M. Across 13 filings, Atlas Venture Life Science Advisors, LLC increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 2,847,541 shares valued at US$318.3M. Notable position changes include a 38% trim in Q2 2026 (shares fell 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.86M | $81.43M | New |
| Q4 2023 | 5.86M | $149.15M | Hold |
| Q1 2024 | 5.38M | $216.17M | Reduce |
| Q2 2024 | 5.35M | $159.71M | Reduce |
| Q3 2024 | 4.90M | $231.75M | Reduce |
| Q4 2024 | 4.90M | $196.98M | Hold |
| Q1 2025 | 4.90M | $134.02M | Hold |
| Q2 2025 | 4.90M | $213.68M | Hold |
| Q3 2025 | 4.90M | $277.14M | Hold |
| Q4 2025 | 4.66M | $362.58M | Reduce |
| Q1 2026 | 4.58M | $381.30M | Reduce |
| Q2 2026 | 2.85M | $326.53M | Reduce |
| Q3 2026 | 2.85M | $318.33M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KYMR and 13F data
KYMR (KYMERA THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in KYMR — the largest reported positions include BAKER BROS. ADVISORS LP (US$992.7M), Avoro Capital Advisors LLC (US$857.1M), T. Rowe Price Investment Management, Inc. (US$717.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KYMR
- BAKER BROS. ADVISORS LP 8.66M sh · $992.73M · Q2 2026
- Avoro Capital Advisors LLC 7.47M sh · $857.13M · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.26M sh · $717.52M · Q2 2026
- BVF INC/IL 3.87M sh · $444.01M · Q2 2026
- Siren, L.L.C. 2.78M sh · $311.32M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 919.23K sh · $105.41M · Q2 2026
- Merck & Co., Inc. 772.16K sh · $88.54M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 740.87K sh · $84.96M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 504.21K sh · $57.81M · Q2 2026
- Rock Springs Capital Management LP 453.16K sh · $51.96M · Q2 2026
- Boxer Capital Management, LLC 429.10K sh · $49.20M · Q2 2026
- BRAIDWELL LP 378.16K sh · $43.36M · Q2 2026
More on Atlas Venture Life Science Advisors, LLC
FAQ
How long has Atlas Venture Life Science Advisors, LLC held KYMR?
Atlas Venture Life Science Advisors, LLC has disclosed KYMR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Atlas Venture Life Science Advisors, LLC's current position in KYMR?
As of Q3 2026, Atlas Venture Life Science Advisors, LLC holds 2.85M shares of KYMR (KYMERA THERAPEUTICS INC), valued at $318.33M, representing 50.43% of its reported portfolio and ranking #1.
Has Atlas Venture Life Science Advisors, LLC been buying or selling KYMR?
In the latest 13F filing (Q3 2026), Atlas Venture Life Science Advisors, LLC held unchanged its position in KYMR. The position peaked in Q1 2026 at 4.58M shares.
Which other funds hold KYMR?
Other major institutional holders of KYMR include BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC, T. Rowe Price Investment Management, Inc., among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.